glp 1 with diverticulitis Is it safe to prescribe glucagon-like peptide‑1 (GLP‑1) receptor agonists for weight loss or glycemic control in a patient diverticulosis? Managing Diverticulitis: Can Ozempic Play

A 2025 study published in JAMA Network Open found that most patients with obesity discontinue GLP-1 therapy within a year, particularly those without type 2 diabetes 1

This study presents some potential limitations, however, such as the timing of sampling and the sensitivity and specificity of the biomarkers

These additions are shown to help support energy metabolism.

Subcutaneous injection delivers the peptide directly into the bloodstream, bypassing digestive degradation making it the preferred route for musculoskeletal or systemic applications

Formulated for Daily Use Gluten-free, vegan-friendly, and made in the USA